Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs

@article{Kirchheiner2005EffectOG,
  title={Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs},
  author={Julia Kirchheiner and Ivar Roots and Mark Goldammer and Bernd Rosenkranz and J{\"u}rgen Brockm{\"o}ller},
  journal={Clinical Pharmacokinetics},
  year={2005},
  volume={44},
  pages={1209-1225}
}
Type 2 diabetes mellitus affects up to 8% of the adult population in Western countries. Treatment of this disease with oral antidiabetic drugs is characterised by considerable interindividual variability in pharmacokinetics, clinical efficacy and adverse effects. Genetic factors are known to contribute to individual differences in bioavailability, drug transport, metabolism and drug action. Only scarce data exist on the clinical implications of this genetic variability on adverse drug effects… Expand
CYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects
TLDR
This review focuses on the effect of CYP2C enzymes on metabolism of sulphonylureas, meglitinides, and thiazolidinediones discussing their impact on pharmacokinetics, drug interactions and toxicological profiles. Expand
Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients
TLDR
The better glycemic control observed can probably be attributed to slower metabolism of SUs by the carriers of the CYP2C9*2/*3 genotype and consequently longer half-life or exacerbated effect of the SUs administered. Expand
Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus
TLDR
Patients with diabetes mellitus who are carriers of a CYP2C9*3 allele require lower doses of tolbutamide to regulate their serum glucose levels compared to patients with the wild‐type genotype. Expand
Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients
TLDR
The type 2 diabetes mellitus patients participating in this study with variant genotypes of CYP2C9 were found to respond better to treatment with glibenclamide than those with the normal genotype. Expand
Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics.
TLDR
The impact of CYP2C polymorphisms on the metabolic fate of small-molecule antidiabetics including sulfonylureas, meglitinides, thiazolidinediones, gliptins, and gliflozins is discussed, with the key drug-protein molecular interactions highlighted. Expand
Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
TLDR
A controlled prospective clinical trial with one arm receiving genotype-based dose adjustments and the other arm receiving therapy as usual will elucidate the benefit of pharmacogenomics-based individualization of certain drug therapies. Expand
The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy
TLDR
The findings can provide guidelines for the optimal management of the treatment protocols with sulfonylurea intended to control the T2D complications and no significant association was found between any of the genotypes as well as the clinical and biochemical characteristics of the patients. Expand
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.
TLDR
The pharmacokinetic parameters of gliclazide MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP1C9 genetic SNP, which is a major cause of liver damage in healthy Chinese subjects. Expand
Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals
TLDR
The present research suggests that the CYP2C8, CYP3A5, and ABCB1 genes play no significant role in the interindividual variation of pioglitazone pharmacokinetics, whereas CYP 2C9*3 carriers are likely to accelerate the metabolism of this antidiabetic drug in the Chinese Han ethnic population. Expand
Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin
TLDR
Within the studied population neither allelic variants nor dosages demonstrated a clear association with biomarker levels, and a key limitation of the present study was the lack of ability to quantify either the plasma concentrations of SU or their metabolites. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 100 REFERENCES
Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
TLDR
The results strongly suggest that the disposition and hypoglycemic effect of tolbutamide are affected mainly by CYP2C9 genetic polymorphism, but not by CYp2C19 polymorphism and that, at least in vivo, tol butamide remains a selective probe for measuring CYP 2C9 activity in humans. Expand
Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers
TLDR
The effect of CYP2C9 polymorphisms on nateglinide kinetics may cause a slightly increased risk for hypoglycaemia, which may become relevant in diabetic patients. Expand
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Cytochrome P450 2C9 (CYP2C9) catalysis the metabolism of important drugs such as phenytoin, S-warfarin, tolbutamide, losartan, torasemide, and nonsteroidal anti-inflammatory drugs. A functionalExpand
Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
TLDR
This study establishes that the Leu359 mutation is responsible for the phenytoin and glipizide/tolbutamide poor metabolizer phenotype. Expand
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
TLDR
Tolbutamide was confirmed as a substrate of the genetically polymorphic enzyme CYP2C9, and the pronounced differences in pharmacokinetics due to the amino acid variants did not significantly affect plasma insulin and glucose concentrations in healthy volunteers. Expand
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.
TLDR
CYP 2C8*3 is defective in the metabolism of two important CYP2C8 substrates: the anticancer drug paclitaxel and the physiologically important compound arachidonic acid. Expand
Genetic analysis of the human cytochrome P450 CYP2C9 locus.
TLDR
Polymerase chain reaction-based assays are developed to distinguish all seven CYP2C9 cDNA sequences, and have determined their allele frequencies in the Caucasian population, allowing the prediction of CYP 2C9 phenotype, thus identifying those individuals who may exhibit different drug pharmacokinetics for CYP1C9 substrates. Expand
Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.
TLDR
Tentative CYP genotype-based dose recommendations systematically calculated from published data are presented, and these doses will not be the optimal doses for each given individual, but should be more adequate than doses generally recommended for an average total population. Expand
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
TLDR
Consistent with the modulation of enzyme activity by genetic and other factors, wide interindividual variability occurs in the elimination and/or dosage requirements of prototypic CYP2C9 substrates. Expand
Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
TLDR
The present study reports the first example of a null polymorphism in CYP2C9, which dramatically affects the half-life and clinical toxicity of phenytoin, and demonstrates the severe clinical consequences to patients with a null mutation after treatment with normal doses of phenYtoin. Expand
...
1
2
3
4
5
...